Navigation Links
For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
Date:9/23/2010

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of multiple myeloma, more surveyed European hematologist-oncologists consider the combination of immunomodulatory agents and proteasome inhibitors promising with respect to efficacy than is the case for any other drug regimen combinations. In light of these findings, the emerging regimen of Onyx Pharmaceuticals' carfilzomib in combination with Celgene's Revlimid has the potential to be the most efficacious strategy for multiple myeloma treatment.

The new European Physician & Payer Forum report entitled European Physician and Payer Perspectives in Myeloma: How Will Emerging Therapies Compete With Well-Entrenched Brands? explores the future market dynamics for this indication in light of several highly-promising emerging agents in multiple myeloma. Although other agents are frequently used to treat the indication, Revlimid, Janssen-Cilag's Velcade and Celgene's Thalidomide together captured more than 80 percent of the multiple myeloma market in 2008 in France, Germany, Italy, Spain and the United Kingdom (EU5).

"Most surveyed European hematologist-oncologists indicate that Velcade is commonly used in the first-line setting while Revlimid-based regimens are more commonly used in the second- and third-line," said Decision Resources Analyst Andrew Merron, Ph.D. "Emerging agents such as carfilzomib are expected to enter the relapsed/refractory settings and will be used either in combination with Revlimid, Velcade and Thalidomide or they will compete directly with these agents. Other key agents in late stage development include Celgene's pomalidomide, AEterna Zentaris/Keryx Biopharmaceuticals' perifosine, Merck's Zolinza and Novartis's panobinostat."  

According to the report, most hematologist-oncologists in the EU5 consider patients who are rel
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
2. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
3. Fertility Drugs Contribute Heavily to Multiple Births
4. Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers
5. Volcano Announces Plans to Introduce Multiple New Products at EuroPCR 2010
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Fortis Hospitals Puts 27 Year Old Nigerian Back on her Feet After Multiple Joint Replacement Surgery
8. SRI International Researchers Present Promising New Therapeutic for the Treatment of Multiple Myeloma
9. Multiple Chemical Sensitivities Are Real
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... VIVUS, Inc. (Nasdaq: VVUS ) today announced ... Drug Administration (FDA) for the New Drug Application (NDA) for ... meeting occurred on January 19th at the FDA,s offices in ... and VIVUS, management and consultants.  At this meeting the FDA ...
... D. Clark Turner, PhD, President and CEO of Aribex, Inc., ... in a ceremony Tuesday night at Discovery Gateway. Utah Governor ... others for providing distinguished service that has benefited the State ... be recognized among the other accomplished individuals who are receiving ...
Cached Medicine Technology:VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3Aribex CEO Receives Utah Governor's Medal 2
(Date:7/13/2014)... York (PRWEB) July 13, 2014 Intraocular ... Trends and Forecast 2013 - 2019 , Intraocular lens ... suffering from myopia or cataracts. The lenses are inserted ... the cataract surgery intraocular lens replaces the focusing power ... with original crystalline lens to deliver the light focusing ...
(Date:7/13/2014)... in Nature Genetics identifies a novel ... causes eosinophillic esophagitis (EoE), opening up potential new ... allergy. , EoE is a chronic inflammatory ... by allergic hypersensitivity to certain foods and an ... called eosinophils (part of the body,s immune system). ...
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... 13, 2014 Chromatography system is ... from various types of biological samples such as ... sample mixture into two phase, namely mobile phase ... phase run over the stationary phase, followed by ... that provide the separation of mixture. Chromatography system ...
(Date:7/13/2014)... July 13, 2014 Recently, MillionaireCasket.com, a well-known ... oak caskets . Additionally, the company’s chief executive officer ... the new oak caskets are offered at discounted prices, from ... am concerned, quality caskets are in huge demand in the ... caskets . We have a lot of high quality ...
Breaking Medicine News(10 mins):Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2
... Report ... July 24 Are you an e-patient?,Studies show that ... information. Thanks to Web 2.0, e-patients now have even ... care and learn about,advanced medical technologies. Go to ...
... helps those with HIV who become treatment-resistant, study shows ... offers more evidence that a new AIDS drug brings ... , The drug, known as raltegravir (Isentress), almost doubles ... virus despite being immune to other medications, according to ...
... HTH Worldwide, a global health and,safety services ... its,CityHealth(R) Profiles to Living Abroad.com and its multi-national ... to trusted,medical care in hundreds of destinations around ... information for those living,overseas or about to be ...
... Health and nutrition researcher Frank,Ervolino, ND, investigated ... the risks associated with stimulants. He reports that,Appetite ... Zurich,Pharmaceuticals, makes novel use of an established ingredient ... to lose weight. In fact, in the,U.S., where ...
... the University of Warwick, Dartmouth College, and the University ... influenced by the weight of those around them. Without ... keep up with the weight of the Joneses. For ... of imitative obesity. The researchers will present their results ...
... adoption of interoperable Health Information Technology (HIT) will ... in the U.S. healthcare system," Yul D. Ejnes, MD, ... on Health today. "Unfortunately, without adequate financial incentives, ... the technological curve." Dr. Ejnes, a member of the ...
Cached Medicine News:Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:Drug Holds Promise Against AIDS 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:New Natural Product from Zurich Pharmaceuticals Downs Appetite 2Health News:Research says fat friends and poor education helps people think thin 2Health News:ACP says Medicare should increase payments for physicians that use HIT to improve quality 2
... the new large power line ... function as both cordless AND ... in flexibility. Its the versatility ... with the security of the ...
... consists of a pistol-grip handpiece available in ... wide range of couplers that can be ... applications., ,MicroAire SmartDriver. Modular Pistol-Grip instrument ... different module for drilling, pinning, cutting, and ...
... Meniscus Implant (CMI) is a type I ... irreparable meniscus tear or loss of meniscus ... procedure. The purpose of the CMI ... and return to a more vigorous lifestyle, ...
... The MicroAire Carpal Tunnel Release System ... surgery. This innovative system, using a minimally-invasive ... small incision at the base of the ... assembly. An endoscope, connected to a standard ...
Medicine Products: